3BNC117 - A Novel Broad-spectrum HIV Neutralizing Antibody

3BNC117 - A Novel Broad-spectrum HIV Neutralizing Antibody
Product Description

3BNC117 is one of the most effective broad-spectrum HIV neutralizing antibodies. Several phase 1 and phase 2 clinical trials have been conducted in the US, showing 3BNC117 not only blocks viral replication like other AIDS drugs, but also induces immune response to HIV and HIV-infected cells. Combining 3BNC117 with ALBUVIRTIDE, we will form an all-injectable, long-acting, two-drug regimen that has novel mechanism of action. We plan to initiate clinical trials in 2018 to test its safety, effectiveness, and potential in eliciting immune response to HIV infection.

Frontier Biotechnologies Inc.

  • CN
  • 2017
    On CPHI since
Specifications
  • Selling Points
    Immune Health; Product Features; Quality Service
  • Supplied from
    China
  • Measured In
    gram; milligram

Frontier Biotechnologies Inc.

  • CN
  • 2017
    On CPHI since

More Products from Frontier Biotechnologies Inc. (2)

  • Albuvirtide for injection - A Long-acting HIV Fusion Inhibitor

    Product Albuvirtide for injection - A Long-acting HIV Fusion Inhibitor

    The world’s first long acting HIV fusion inhibitor. An amino acid synthesized peptide, lyophilized powder for injection with shelf life 24 months. The API should be stored and transported at -20C, and the finished product should be stored and transported at 2-8C. ALBUVIRTIDE only need to be ad...
  • AB001 -A new transdermal patch for musculoskeletal

    Product AB001 -A new transdermal patch for musculoskeletal

    A third generation topical patch for the management of pain and inflammation. - Long half life; once daily dosage with relatively shorter administration period provides efficacy with less skin irritation/inflammation. - Patch is non-hydrogel, alcohol-free formulation.- Patch matrix formulation is onl...